These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 24913512)

  • 21. Anthracycline-related cardiotoxicity in older patients with acute myeloid leukemia: a Young SIOG review paper.
    Neuendorff NR; Loh KP; Mims AS; Christofyllakis K; Soo WK; Bölükbasi B; Oñoro-Algar C; Hundley WG; Klepin HD
    Blood Adv; 2020 Feb; 4(4):762-775. PubMed ID: 32097461
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical decision making based on radionuclide determined ejection fraction in oncology patients.
    Peng NJ; Advani R; Kopiwoda S; Fisher G; Strauss HW
    J Nucl Med; 1997 May; 38(5):702-5. PubMed ID: 9170431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Combination chemotherapy for acute myeloid leukemia].
    Nagai T
    Nihon Rinsho; 2009 Oct; 67(10):1921-5. PubMed ID: 19860191
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute myeloid leukemia in the elderly: etoposide when anthracyclins are contraindicated.
    Chaoui D; Peffault De Latour R; Legrand O; Marie JP
    Leuk Lymphoma; 2005 Mar; 46(3):401-4. PubMed ID: 15621830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Current therapeutic strategies in the management of acute myeloid leukemia].
    Fiegl M; Hiddemann W; Braess J
    Med Klin (Munich); 2007 Apr; 102(4):309-16. PubMed ID: 17426934
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
    Röllig C; Serve H; Hüttmann A; Noppeney R; Müller-Tidow C; Krug U; Baldus CD; Brandts CH; Kunzmann V; Einsele H; Krämer A; Schäfer-Eckart K; Neubauer A; Burchert A; Giagounidis A; Krause SW; Mackensen A; Aulitzky W; Herbst R; Hänel M; Kiani A; Frickhofen N; Kullmer J; Kaiser U; Link H; Geer T; Reichle A; Junghanß C; Repp R; Heits F; Dürk H; Hase J; Klut IM; Illmer T; Bornhäuser M; Schaich M; Parmentier S; Görner M; Thiede C; von Bonin M; Schetelig J; Kramer M; Berdel WE; Ehninger G;
    Lancet Oncol; 2015 Dec; 16(16):1691-9. PubMed ID: 26549589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current treatment of acute myeloid leukemia.
    Roboz GJ
    Curr Opin Oncol; 2012 Nov; 24(6):711-9. PubMed ID: 23014187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.
    Megías-Vericat JE; Montesinos P; Herrero MJ; Moscardó F; Bosó V; Rojas L; Martínez-Cuadrón D; Hervás D; Boluda B; García-Robles A; Rodríguez-Veiga R; Martín-Cerezuela M; Cervera J; Sendra L; Sanz J; Miguel A; Lorenzo I; Poveda JL; Sanz MÁ; Aliño SF
    Leuk Lymphoma; 2017 May; 58(5):1197-1206. PubMed ID: 27701910
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the Study Alliance Leukemia.
    Müller-Tidow C; Tschanter P; Röllig C; Thiede C; Koschmieder A; Stelljes M; Koschmieder S; Dugas M; Gerss J; Butterfaß-Bahloul T; Wagner R; Eveslage M; Thiem U; Krause SW; Kaiser U; Kunzmann V; Steffen B; Noppeney R; Herr W; Baldus CD; Schmitz N; Götze K; Reichle A; Kaufmann M; Neubauer A; Schäfer-Eckart K; Hänel M; Peceny R; Frickhofen N; Kiehl M; Giagounidis A; Görner M; Repp R; Link H; Kiani A; Naumann R; Brümmendorf TH; Serve H; Ehninger G; Berdel WE; Krug U;
    Leukemia; 2016 Mar; 30(3):555-61. PubMed ID: 26522083
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intensive chemotherapy and reduced-intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in elderly patients.
    Jackson K; Kennedy G; Mollee P; Marlton P; Morris K
    Asia Pac J Clin Oncol; 2014 Sep; 10(3):246-54. PubMed ID: 24673966
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
    Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
    Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monitoring of cardiac function on the basis of serum troponin I levels in patients with acute leukemia treated with anthracyclines.
    Specchia G; Buquicchio C; Pansini N; Di Serio F; Liso V; Pastore D; Greco G; Ciuffreda L; Mestice A; Liso A
    J Lab Clin Med; 2005 Apr; 145(4):212-20. PubMed ID: 15962840
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CLAG-based induction therapy in previously untreated high risk acute myeloid leukemia patients.
    Seiter K; Ahmed N; Shaikh A; Baskind P; Liu D
    Leuk Res; 2016 Jul; 46():74-8. PubMed ID: 27151544
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The expression of Toll-like receptors in patients with acute myeloid leukemia treated with induction chemotherapy.
    Rybka J; Butrym A; Wróbel T; Jaźwiec B; Stefanko E; Dobrzyńska O; Poręba R; Kuliczkowski K
    Leuk Res; 2015 Mar; 39(3):318-22. PubMed ID: 25624047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The fate of patients with acute myeloid leukemia not undergoing induction chemotherapy.
    Yanada M; Okamoto A; Inaguma Y; Tokuda M; Morishima S; Kanie T; Yamamoto Y; Mizuta S; Akatsuka Y; Okamoto M; Emi N
    Int J Hematol; 2015 Jul; 102(1):35-40. PubMed ID: 25822047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evolving Therapies in Acute Myeloid Leukemia: Progress at Last?
    DeAngelo DJ; Stein EM; Ravandi F
    Am Soc Clin Oncol Educ Book; 2016; 35():e302-12. PubMed ID: 27249736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Efficacy of granisetron for preventing chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia treated with a combination of anthracycline and cytarabine].
    Goto T; Tanimoto K; Ishibashi M; Okamura S
    Gan To Kagaku Ryoho; 2012 Aug; 39(8):1227-32. PubMed ID: 22902447
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HAG regimen improves survival in adult patients with hypocellular acute myeloid leukemia.
    Hu X; Fu W; Wang L; Gao L; Lü S; Xi H; Qiu H; Chen L; Chen J; Ni X; Xu X; Zhang W; Yang J; Wang J; Song X
    Oncotarget; 2016 Jan; 7(3):3623-34. PubMed ID: 26497216
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Routine interim disease assessment in patients undergoing induction chemotherapy for acute myeloid leukemia: Can we do better?
    Campuzano-Zuluaga G; Deutsch Y; Salzberg M; Gomez A; Vargas F; Elias R; Kwon D; Goodman M; Ikpatt OF; Chapman JR; Watts J; Vega F; Swords R
    Am J Hematol; 2016 Mar; 91(3):277-82. PubMed ID: 26663264
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Need for routine examination of left ventricular ejection fraction in patients with AML.
    Khan HM; Gardner KM; Shaw C; Halpern AB; Huebner EM; Percival MM; Mirahsani S; Sorror ML; Becker PS; Walter RB; Estey EH
    Leukemia; 2020 Apr; 34(4):1169-1171. PubMed ID: 31719680
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.